Vivos Therapeutics is acquiring an 11% stake in SOD Sciences and a 50% interest in a pseudohypoxia early-warning test, valued at $12 million, paid in newly created Series C Convertible Preferred Stock. This non-cash transaction aims to boost Vivos' stockholders' equity, potentially helping it regain Nasdaq compliance, and opens doors for collaborations with Cleveland Clinic and American Health Associates.
Vivos Therapeutics is making a strategic move by acquiring an 11% equity interest in SOD Sciences and a 50% co-ownership in a proprietary pseudohypoxia early-warning test. This transaction, valued at $12 million and paid entirely in Series C Convertible Preferred Stock, is significant because it's a non-cash deal designed to increase Vivos' reported stockholders' equity, which is crucial for regaining compliance with Nasdaq listing rules. The deal also opens doors for important collaborations with the Cleveland Clinic and a marketing relationship with American Health Associates, potentially expanding Vivos' reach and research capabilities. Short-term, the market will likely react positively to the potential for Nasdaq compliance and strategic partnerships. Long-term, the success hinges on the value generated from the acquired assets and collaborations, and Vivos' ability to raise capital and achieve profitability by early 2027. A key opportunity for traders is the potential upside if Vivos successfully regains Nasdaq compliance and leverages these new relationships.